Quick Answer
Grace Therapeutics, Inc. reported Net Income of -$9.57 million for fiscal year 2025.
Grace Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$9.57M +25.6% |
-$12.85M +69.7% |
-$42.43M -332.1% |
-$9.82M +50.1% |
-$19.68M +22.9% |
-$25.51M +35.2% |
| Diluted EPS | -$0.79 +41.5% |
-$1.35 +76.4% |
-$5.71 -2014.8% |
-$0.27 | — | — |
| Total Assets | $71.99M -1.8% |
$73.30M -7.4% |
$79.12M -38.5% |
$128.62M +105.9% |
$62.46M +173.3% |
$22.85M -38.1% |
| Cash and Equivalents | $22.13M -3.8% |
$23.00M -17.5% |
$27.88M -8.1% |
$30.34M -40.4% |
$50.94M +257.7% |
$14.24M -15.6% |
| Stockholders Equity | $66.61M +7.9% |
$61.74M -9.1% |
$67.95M -37.2% |
$108.27M +94.5% |
$55.66M +328.4% |
$12.99M +17.6% |
| R&D Expense | $9.51M +103.1% |
$4.68M -53.0% |
$9.97M +79.4% |
$5.56M +33.2% |
$4.17M -73.9% |
$15.97M -45.6% |
| Operating Income | -$16.68M -29.8% |
-$12.85M +75.4% |
-$52.16M -234.6% |
-$15.59M +5.1% |
-$16.42M +32.8% |
-$24.44M +29.0% |
| Shares Outstanding | — | 9.40M +26.4% |
7.44M -83.2% |
44.29M | — | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | December 31, 2025 | -$2.31M | +44.3% | -146.8% |
| Diluted EPS | December 31, 2025 | -$0.14 | +61.1% | -133.3% |
| Total Assets | December 31, 2025 | $68.49M | +11.9% | +2.9% |
| Cash and Equivalents | December 31, 2025 | $18.67M | +68.9% | +10.7% |
| Stockholders Equity | December 31, 2025 | $64.89M | +24.5% | +3.3% |
| R&D Expense | December 31, 2025 | $462.0K | -78.9% | -18.7% |
| Operating Income | December 31, 2025 | -$2.45M | +33.9% | +3.2% |
| Shares Outstanding | December 31, 2025 | 15.47M | +52.6% | +9.5% |
- Grace Therapeutics, Inc. reported Net Income of -$9.57 million for fiscal year 2025.
- Grace Therapeutics, Inc. showed an increase of +25.6% in Net Income compared to the prior fiscal year.
- Grace Therapeutics, Inc. reported Diluted EPS of $0.79 per share (loss) for fiscal year 2025.
- Grace Therapeutics, Inc. showed an increase of +41.5% in Diluted EPS compared to the prior fiscal year.
- Grace Therapeutics, Inc. reported Total Assets of $71.99 million for fiscal year 2025.
- Grace Therapeutics, Inc. showed a decrease of -1.8% in Total Assets compared to the prior fiscal year.
- Grace Therapeutics, Inc. reported Cash and Equivalents of $22.13 million for fiscal year 2025.
- Grace Therapeutics, Inc. showed a decrease of -3.8% in Cash and Equivalents compared to the prior fiscal year.
- Grace Therapeutics, Inc. reported Stockholders Equity of $66.61 million for fiscal year 2025.
- Grace Therapeutics, Inc. showed an increase of +7.9% in Stockholders Equity compared to the prior fiscal year.
- Grace Therapeutics, Inc. reported R&D Expense of $9.51 million for fiscal year 2025.
- Grace Therapeutics, Inc. showed an increase of +103.1% in R&D Expense compared to the prior fiscal year.
- Grace Therapeutics, Inc. reported Operating Income of -$16.68 million for fiscal year 2025.
- Grace Therapeutics, Inc. showed a decrease of -29.8% in Operating Income compared to the prior fiscal year.
- Grace Therapeutics, Inc. reported Shares Outstanding of 9.40 million shares for fiscal year 2024.
- Grace Therapeutics, Inc. showed an increase of +26.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: